Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–21. https://doi.org/10.1177/1352458520970841.

Article  PubMed  PubMed Central  Google Scholar 

Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40. https://doi.org/10.1111/ene.13819.

Article  CAS  PubMed  Google Scholar 

Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132–40. https://doi.org/10.1001/jamaneurol.2020.1568.

Article  PubMed  Google Scholar 

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33:1444–52. https://doi.org/10.1212/wnl.33.11.1444.

Article  CAS  PubMed  Google Scholar 

Lavery AM, Verhey LH, Waldman AT. Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int. 2014;2014: 262350. https://doi.org/10.1155/2014/262350.

Article  PubMed  PubMed Central  Google Scholar 

Braune S, Rossnagel F, Dikow H, Bergmann A, NeuroTransData Study Group. Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry. BMJ Open. 2021;11(8): e042480. https://doi.org/10.1136/bmjopen-2020-042480.

Article  PubMed  PubMed Central  Google Scholar 

Trisolini MA, Honeycutt A, Wiener J, Lesesne S. Global economic impact of multiple sclerosis. In: Multiple Sclerosis International Federation. 2010. https://www.msif.org/wp-content/uploads/2014/09/Global_economic_impact_of_MS.pdf. Accessed 13 Jul 2023.

Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group; European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–36. https://doi.org/10.1177/1352458517694432.

Article  PubMed  PubMed Central  Google Scholar 

Flachenecker P, Kobelt G, Berg J, Capsa D, Gannedahl M, European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Germany. Mult Scler. 2017;23(2_suppl):78–90. https://doi.org/10.1177/1352458517708141.

Article  PubMed  Google Scholar 

Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18(2 Suppl):7–15. https://doi.org/10.1177/1352458512441566.

Article  PubMed  Google Scholar 

Karampampa K, Gyllensten H, Yang F, et al. Healthcare, sickness absence, and disability pension cost trajectories in the first 5 years after diagnosis with multiple sclerosis: a prospective register-based cohort study in Sweden. Pharmacoecon Open. 2020;4(1):91–103. https://doi.org/10.1007/s41669-019-0150-3.

Article  PubMed  Google Scholar 

Ernstsson O, Gyllensten H, Alexanderson K, Tinghög P, Friberg E, Norlund A. Cost of illness of multiple sclerosis - a systematic review. PLoS ONE. 2016;11(7): e0159129. https://doi.org/10.1371/journal.pone.0159129.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gyllensten H, Kavaliunas A, Murley C, et al. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Mult Scler J Exp Transl Clin. 2019;5(2):2055217319858383. https://doi.org/10.1177/2055217319858383.

Article  PubMed  PubMed Central  Google Scholar 

Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990;40(6):971–5. https://doi.org/10.1212/wnl.40.6.971.

Article  CAS  PubMed  Google Scholar 

Cadavid D, Cohen JA, Freedman MS, et al. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017;23(1):94–105. https://doi.org/10.1177/1352458516638941.

Article  PubMed  Google Scholar 

Meyer-Moock S, Feng Y-S, Maeurer M, Dippel F-W, Kohlmann T. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58. https://doi.org/10.1186/1471-2377-14-58.

Article  PubMed  PubMed Central  Google Scholar 

Mitchell AJ, Benito-León J, Morales González J-M, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005;4(9):556–66. https://doi.org/10.1016/S1474-4422(05)70166-6.

Article  PubMed  Google Scholar 

Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler. 2005;11(5):602–9. https://doi.org/10.1191/1352458505ms1204oa.

Article  PubMed  Google Scholar 

Cadden M, Arnett P. Factors associated with employment status in individuals with multiple sclerosis. Int J MS Care. 2015;17(6):284–91. https://doi.org/10.7224/1537-2073.2014-057.

Article  PubMed  PubMed Central  Google Scholar 

Oliva Ramirez A, Keenan A, Kalau O, Worthington E, Cohen L, Singh S. Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol. 2021;21(1):468. https://doi.org/10.1186/s12883-021-02396-1.

Article  PubMed  PubMed Central  Google Scholar 

Gustavsen S, Olsson A, Søndergaard HB, et al. The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey. BMC Neurol. 2021;21(1):317. https://doi.org/10.1186/s12883-021-02344-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dillon P, Heer Y, Karamasioti E, et al. The socioeconomic impact of disability progression in multiple sclerosis: a retrospective cohort study of the German NeuroTransData (NTD) registry. Mult Scler J Exp Transl Clin. 2023;9(3):20552173231187810. https://doi.org/10.1177/20552173231187810.

Article  PubMed  PubMed Central  Google Scholar 

NeuroTransData GmbH. NTD database. 2022. https://www.neurotransdata.com/en/. Accessed 8 Apr 2022.

Smith A. Symbol digit modalities test. Los Angeles: Western Psychological Services; 1973.

Google Scholar 

D’Souza E. Modified Fatigue Impact Scale–5-item version (MFIS-5). Occup Med (Lond). 2016;66(3):256–7. https://doi.org/10.1093/occmed/kqv106.

Article  PubMed  Google Scholar 

Mathiowetz V, Weber K, Kashman N, Volland G. Adult norms for the nine hole peg test of finger dexterity. Occup Ther J Res. 1985;5(1):24–38. https://doi.org/10.1177/153944928500500102.

Article  Google Scholar 

Bethoux FA, Palfy DM, Plow MA. Correlates of the timed 25 foot walk in a multiple sclerosis outpatient rehabilitation clinic. Int J Rehabil Res. 2016;39(2):134–9. https://doi.org/10.1097/MRR.0000000000000157.

Article  PubMed  PubMed Central  Google Scholar 

Bergmann A, Stangel M, Weih M, et al. Development of registry data to create interactive doctor-patient platforms for personalized patient care, taking the example of the DESTINY System. Front Digit Health. 2021;3: 633427. https://doi.org/10.3389/fdgth.2021.633427.

Article  PubMed  PubMed Central  Google Scholar 

Wehrle K, Tozzi V, Braune S, et al. Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data (RWD) in the NeuroTransData (NTD) registry. JAMIA Open. 2022;5(1):ooac017. https://doi.org/10.1093/jamiaopen/ooac017.

Article  PubMed  PubMed Central  Google Scholar 

Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36(6):663–74. https://doi.org/10.1007/s40273-018-0615-8.

Article  PubMed  PubMed Central